Loading…
Loading…
On October 12, 2026, Bioventus Inc (BVS) shares rose 3.6% today, currently priced at $13.53. This move comes amid a 52-week range of $6.46 to $15.89.GF Valueâ¢
Bioventus (NASDAQ: BVS - Get Free Report) and Kestra Medical Technologies (NASDAQ: KMTS - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Risk and Volatility Bioventus has a beta
RxSight (NASDAQ: RXST - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability. Analyst Ratings This is a summary of recent recommendations
Bioventus leverages cash from established products to reduce debt and fund commercial expansion, supporting a bullish outlook. BVS benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. Execution focus is on demonstrating sustained cash flows, successful new product adoption, and repeat physician usage, not just early launch revenue.
Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript